Regeneron Pharmaceuticals
$735.20Change from previous close: +0.05%Absolute change: +$0.39
At a glance
- Revenue growth
- +0.99%
- 2025 vs 2024
- Net income growth
- +2.09%
- 2025 vs 2024
- Net margin
- 31.4%
- 2024: 31.1%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 4,979 | 4,421 | 4,594 | 5,015 | 7,081 |
| Depreciation and amortization | 544 | 483 | 421 | 341 | 286 |
| Capital expenditure | -898 | -756 | -719 | -590 | -552 |
| Investing cash flow | -629 | -2,468 | -3,185 | -3,785 | -5,385 |
| Financing cash flow | -3,715 | -2,201 | -1,790 | -1,009 | -1,006 |
| Dividends paid | -370 | 0.0 | 0.0 | — | — |
| Share repurchases | -3,971 | -3,632 | -2,936 | -2,529 | -2,678 |
| Debt issued | — | — | — | 0.0 | 0.0 |
| Debt repaid | — | — | — | 0.0 | 0.0 |
| Effect of exchange rates | 0.3 | -0.7 | -0.4 | 0.0 | — |
| Net change in cash | 635 | -249 | -382 | 221 | 691 |
| Free cash flow | 4,081 | 3,665 | 3,875 | 4,425 | 6,529 |
| Levered free cash flow | 3,258 | 2,636 | 2,763 | 2,628 | 4,309 |